AstraZeneca Demonstrates Commitment to R&D Investment at Innovation Conference in Moscow

Tuesday, 22 February 2011

The international “Innovation in Russian Healthcare” conference in Moscow on 22 February 2010 made an important contribution to the discussion of how to bridge the gap between developments in fundamental science and commercial success in the pharmaceutical and healthcare market.

AstraZeneca Russia co-hosted the conference along with the British Embassy in Russia and UK Trade and Investment; the Skolkovo Innovation Center, an innovation hub supported by the Russian President Dmitriy Medvedev; and Russian Venture Company.

The event gave participants the opportunity to hear from keynote speakers and panel discussions about international best practices.

Signing with Skolkovo

A highlight of the conference was the signing of a memorandum of understanding between AstraZeneca Russia and the Russian innovation foundation Skolkovo. The parties plan to combine their efforts in support of Russian innovation and new medicines development.

An initial project of the partnership is the Virtual Research Institute (VRI), a grants programme which aims to motivate Russian scientists to conduct their R&D activities in Russia rather than abroad.

We invest over $4 billion in R&D annually; AstraZeneca is experienced in efficient R&D partnership and we have over 1,200 collaborations worldwide. We are glad to have an opportunity to implement the global mechanism of R&D partnership in Russia. Today’s investments in Russian science demonstrate AstraZeneca’s long-term intention to be in Russia for Russia.

Nenad Pavletic

President of AstraZeneca Russia

The value of partnering

Speakers at the conference included our Head of R&D for Asia & Emerging Markets, Steve Yang. The speakers discussed perspectives for developing and commercialising innovative biopharmaceutical projects, and it was agreed that joint efforts will greatly benefit the development of healthcare innovations.

Steve Yang, Head of R&D for Asia & Emerging Markets

Missing translation key: locale='en_US', key='astrazeneca/Video:NoFlashOrJavaScript'

Steve Yang discusses the rich opportunities for healthcare innovation at Moscow conference.

Science and technology have never been so promising or delivered so many opportunities to improve global health and extend people’s lives. But the drug development process is incredibly costly, risky, and time-consuming. As Russia enters an era of unprecedented opportunity in science, AstraZeneca is committed to being its long-term partner in revitalizing pharmaceutical innovation. We would like to share with the Russian pharmaceutical science our research expertise and experience in developing innovations.

The conference is a good start and will be followed by further events in 2011 to help further support the development of healthcare innovation in Russia.

About the event

Russian conference

(left to right):

  • Igor Goryanin, Head of Biological and Medical technologies cluster of Innovative Center 'Skolkovo';
  • Steve Yang, Vice President, AstraZeneca, R&D, Emerging Markets and Asia;
  • Rt Hon David Willetts, MP, British Minister of State for Universities and Science;
  • Nenad Pavletic,President of AstraZeneca Russia.

The event was attended by over 150 people including government representatives, scientists and businessmen from Russia, the UK and the European Union. Participants included Rt Hon David Willetts, MP, British Minister of State for Universities and Science, Arkady Dvorkovich, Assistant to the Russian Federation President, Veronika Skvortsova, Deputy Minister of Healthcare and Social Development, Olga Borzova, the Chairman of Healthcare Committee of the State Duma, Sergey Tsyb, Director of the Department of Chemical and Technical Complex and Bioengineering Technologies, Ministry of Industry and Trade. AstraZeneca was represented by Steve Yang, Head of R&D for Asia & Emerging Markets, with responsibility for our R&D investments in Russia and Denise Goode, Executive Business Development Director, who has responsibility for delivering regional and commercial deals.